8-K: AN2 Therapeutics Reports Disappointing Phase 3 Data for EBO-301, Shifts Focus to Boron Chemistry Pipeline

AN2 Therapeutics' Phase 3 trial for EBO-301 in MAC lung disease failed to meet its primary endpoint, leading the company to prioritize its boron chemistry pipeline and other clinical programs.

Summary

• AN2 Therapeutics announced topline results from the Phase 3 portion of the EBO-301 study, which evaluated epetraborole for treatment-refractory MAC lung disease, and the study did not meet its primary endpoint.
• The company is shifting its focus to its boron chemistry pipeline, which includes clinical programs in infectious diseases and an emerging oncology portfolio.
• AN2 has initiated start-up activities for a Phase 1 clinical study of AN2-502998 for chronic Chagas disease, with topline data for a standard-of-care melioidosis observational trial expected in 2Q25 and a Phase 2 study planned for 2H25.
• The company anticipates advancing its first oncology compound(s) into development in 2H25, targeting ENPP1, PI3K, and other undisclosed targets for solid tumor indications.
• AN2 Therapeutics projects its existing cash and cash equivalents will sustain operating plans into 2028, with $78.5 million in cash, cash equivalents, and investments as of March 31, 2025.
• The company has implemented strategic measures to optimize operations and enhance shareholder value, including a workforce reduction and pipeline reprioritization.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While the Phase 3 trial failed, the company is pivoting to other programs and has extended its cash runway. The focus on new programs and potential future milestones balances the negative news of the failed trial.

Positives

• AN2 Therapeutics is shifting its focus to its boron chemistry pipeline, which includes clinical programs in infectious diseases and an emerging oncology portfolio.
• A Phase 1 clinical study of AN2-502998 for chronic Chagas disease has been initiated, with a peak annual sales potential estimated at $1 billion.
• A Phase 2 study with epetraborole in melioidosis is planned for 2H25, aiming to reduce the 3-month mortality rate of approximately 40%.
• The company expects to advance its first oncology compound(s) into development in 2H25, targeting ENPP1 and PI3K.
• AN2 Therapeutics extends its cash runway into 2028 and had $78.5 million in cash, cash equivalents, and investments as of March 31, 2025.
• The company is pursuing non-dilutive funding for several key programs.

Negatives

• The Phase 3 portion of the EBO-301 study evaluating epetraborole in treatment-refractory MAC lung disease did not meet its primary endpoint.
• The EBO-301 study population included patients with severe, advanced MAC lung disease with a long duration of disease, high rates of cavitary/fibrocavitary disease, and multidrug resistance to standard of care antibiotics at baseline.

Risks

• The company's forward-looking statements involve significant risks and uncertainties, including the ability to implement its plans for its boron chemistry platform and pipeline programs.
• There are risks related to timely enrollment of patients in clinical trials, potential for results from clinical trials to differ from preclinical results, and the uncertainty associated with product candidates receiving regulatory approvals.
• The company's ability to obtain, maintain, or protect intellectual property rights related to its current and future product candidates is a risk.
• Global macroeconomic conditions and global conflicts could impact the company's performance.

Future Outlook

AN2 Therapeutics projects that its existing cash and cash equivalents will sustain its operating plans into 2028. The company plans to advance its boron chemistry pipeline, including programs in Chagas disease, melioidosis, and oncology.

Management Comments

• Eric Easom, Co-founder, Chairman, President and CEO, stated that while disappointed in the EBO-301 results, there is potential for epetraborole in other NTM populations.
• Eric Easom highlighted the significant progress on the boron chemistry pipeline with several high impact clinical programs in infectious diseases and an emerging oncology portfolio.
• Eric Easom noted that the clinical programs in Chagas and melioidosis feature first-in-class molecules with the potential to significantly reduce the mortality and impact of these devastating diseases.
• Eric Easom mentioned that the company has leveraged its boron chemistry capabilities to identify multiple oncology candidates including potentially best-in-class inhibitors for ENPP1 and PI3K with the lead compound(s) expected to enter development later this year.

Industry Context

The failure of the EBO-301 study highlights the challenges in treating severe, advanced MAC lung disease. The company's shift to its boron chemistry pipeline reflects a broader trend in the pharmaceutical industry towards developing novel small molecule therapeutics for infectious diseases and oncology.

Comparison to Industry Standards

• The company's AN2-502998 works via the same mechanism of action as acoziborole, a single oral dose cure for human African trypanosomiasis (sleeping sickness), a related disease caused by trypanosome parasites, that demonstrated up to a 95% cure rate in a Phase 3 trial conducted by DNDi/Sanofi.
• The company plans to initiate a Phase 2 study with epetraborole in melioidosis, a potentially lethal bacterial infection and a U.S. national security threat, with a goal of significantly reducing the 3-month mortality rate of ~40% observed in a recent standard-of-care observational trial.

Stakeholder Impact

• Shareholders may be concerned about the failed Phase 3 trial but encouraged by the company's shift to other programs and extended cash runway.
• Employees may be affected by the strategic reduction in workforce.
• Patients with Chagas disease, melioidosis, and cancer may benefit from the company's pipeline programs.

Next Steps

• Initiate Phase 1 clinical study of AN2-502998 for chronic Chagas disease.
• Complete Phase 1 clinical study of AN2-502998 in 2H25.
• Obtain topline data for standard-of-care melioidosis observational trial in 2Q25.
• Initiate Phase 2 study with epetraborole in melioidosis in 2H25.
• Advance first oncology compound(s) into development in 2H25.

Key Dates

Keywords

AN2 Therapeutics, boron chemistry, EBO-301, epetraborole, Chagas disease, melioidosis, oncology, clinical trials, NTM, AN2-502998